Research programme: casein kinase inhibitors - Pfizer

Drug Profile

Research programme: casein kinase inhibitors - Pfizer

Latest Information Update: 02 Sep 2011

Price : $50

At a glance

  • Originator Pfizer
  • Class Pyrazoles; Pyrimidines
  • Mechanism of Action Casein kinase Idelta inhibitors; Casein kinase Iepsilon inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Cancer; Psychiatric disorders

Most Recent Events

  • 01 Sep 2011 Early research is ongoing in USA
  • 13 Nov 2010 Early research in Cancer in USA (unspecified route)
  • 13 Nov 2010 Early research in Psychiatric disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top